# Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology

Study · id `cardio:ct-nct01624064` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01624064](<https://clinicaltrials.gov/study/NCT01624064>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01624064

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01624064. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2012-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01624064, source copy `cardio:ctgov-nct01624064-2012-06-20`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01624064, source copy `cardio:ctgov-nct01624064-2012-06-20`, retrieved 2026-10-26)
- Primary completion: 2012-10 (anticipated) (ClinicalTrials.gov record NCT01624064, source copy `cardio:ctgov-nct01624064-2012-06-20`, retrieved 2026-10-26)
- Completion: 2013-10 (anticipated) (ClinicalTrials.gov record NCT01624064, source copy `cardio:ctgov-nct01624064-2012-06-20`, retrieved 2026-10-26)
- Countries: Sri Lanka (ClinicalTrials.gov record NCT01624064, source copy `cardio:ctgov-nct01624064-2012-06-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01624064-2012-06-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology
- Acronym: CKDu
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Enalapril
- Intervention (Drug): Calcium Supplement
- Lead sponsor: Ministry of Health, Sri Lanka
- Lead sponsor class: OTHER\_GOV
- Collaborator: World Health Organization
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as a collaborator: World Health Organization (`cardio:who`)

## Provenance

Content hash: 8692d47fa525f9cb425a1b02f6862f9bf8291c048c4a98affe6a8c385585cc14
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
